You are here » Home » Companies » Company Overview » Kilpest India Ltd

Kilpest India Ltd.

BSE: 532067 Sector: Agri and agri inputs
NSE: N.A. ISIN Code: INE994E01018
BSE 00:00 | 17 Aug 380.15 14.80
(4.05%)
OPEN

364.00

HIGH

383.00

LOW

353.25

NSE 05:30 | 01 Jan Kilpest India Ltd
OPEN 364.00
PREVIOUS CLOSE 365.35
VOLUME 11096
52-Week high 560.65
52-Week low 281.00
P/E 37.53
Mkt Cap.(Rs cr) 285
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 364.00
CLOSE 365.35
VOLUME 11096
52-Week high 560.65
52-Week low 281.00
P/E 37.53
Mkt Cap.(Rs cr) 285
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Kilpest India Ltd. (KILPESTINDIA) - Chairman Speech

Company chairman speech

Before we start with the review of the financial and business results of the fiscalyear 2020-21 I would like to take a moment to express my condolences and pay my respectsto all our employees shareholders suppliers and customers who have suffered loss offamily members friends colleagues or loved ones due to the Coronavirus which cannot beaccounted for and is immeasurable in all terms. This pandemic has taken a gigantic toll onthe mankind around the world. We are all together in this hour of grief. Let us all honourand cherish the memories of the people who have left us too soon and keep them alive inthe works we do ahead.

Year 2020 and 2021 made its mark in the timelines of millions. It has brought bigchanges in people's life and society. I am proud to announce that Year 2020-21 hasunveiled the never ending commitment and dedication to bringing a change in the people'slife by providing world-class and affordable agro and healthcare solutions.

In the beginning of March when India started reporting increasing cases of this newvirus COVID-19 and we got ourselves into developing the RT-PCR based kit for its testingwhich was declared by WHO as the gold standard technique to test patient samples for thepresence of Virus.

We got the Approval from ICMR on 2nd April 2020 and license from CDSCO on 4th April2020 to manufacture and sell RT-PCR Kit for COVID-19 under its brand name TRUPCRSARS-CoV-2 RT qPCR Kit (Real-Time PCR based detection of SARS-CoV-2 virus) Version 2.0 fordetection of SARS-CoV-2. The company also launched in June 2020 its single tube multiplexassay for TRUPCR SARS-CoV-2 RT qPCR Kit (Real-Time PCR based detection of SARS-CoV-2virus) Version 3.2.

Shortly after the approvals demand skyrocketed and from the production capacityof5000 tests a day we started scaling up our efforts to produce more than 100000 testsper day. We thankfully acknowledge the efforts made by our team who pulled off theproduction and deliveries successfully even during the lockdown and made sure that thetests reach the laboratories.

It was June 2020 when we became FIRST EVER Indian molecular diagnostics company toreceive US-FDA EUA (Emergency Use Authorization) to make our mark on the global IVDindustry. We further also received EUA on our RT-PCR kit for Saliva samples. With that webecame the 5th company in the world to offer US-FDA approved solution for saliva sampletesting for patients.

Even with the tough competition the company was able to sell over 7 million tests bythe end of FY 2020-21 and in April-May 21 we sold close to 3 million tests taking ourtotal figure to over 10 Million which is a big milestone and a matter of pride for thecompany.

Our kits are being used by more than 400 private laboratories and an almost equalnumber of government laboratories and each of the customers rely on our quality. It isoverwhelming to see how our users have placed multiple repeat orders with us even thoughthere were more than 100 different kits available with time.We are proud to say that ourtests have saved millions of lives and supported the country to take a step forwardtowards being self-dependent in healthcare services.There is never a more satisfyingfeeling than seeing our vision becoming reality. A vision of providing world-classaffordable healthcare solutions to all!

Our numbers speak for our adventurous journey and the dedicated focused efforts of ourentire team without whom this achievement was impossible. Moving forward into the year2021-22 we believe that the company will continue to grow both for our COVID andNon-COVID businesses globally.

.